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PDB1
DIABETIC MANAGEMENT THROUGH ORAL 
GLUCOSE LOWERING AGENTS: TREATMENT 
PATTERN, COST AND UTILIZATION ANALYSIS
Thompson FD1, Rosenblum MS2, O’Neill JM2, Celebi D1, 
Olmsted E1
1IHCIS, Lexington, MA, USA; 2Integrail, Latham, NY, USA
OBJECTIVES: Assess the treatment progression of Type
2 diabetic patients taking glimepiride, glipizide xl, and/or
metformin as initial monotherapy and the impact these
agents have on the cost and utilization of health care ser-
vices. METHOD: Medical and pharmacy claims data for
7,585 patients meeting inclusion criteria were collected
from a national managed care database representing 6
million lives in 23 US health plans and 8 geographic re-
gions over a 4 year period. Cohorts by agents were cre-
ated based on diabetes type and initial treatment agent.
Cost and utilization analysis included evaluation of pa-
tients by age, gender, geographic region, type of medical
service and provider speciality. Diagnosis codes were
used to differentiate between all health care services and
disease related services. Treatment analysis evaluated
treatment progression, compliance with therapy and dose
progression. Treatment efficacy and practice patterns in
five possible outcomes were defined for each cohort. RE-
SULTS: The highest proportion of patients in each co-
hort remained on the initial therapy. Combination ther-
apy was the most frequent therapeutic choice for patients
failing monotherapy. Evaluation of the maximum daily
dose (MDD) showed patients who were switched to an
alternate agent of the same class reached 41–48% of
MDD, a different class 49–57% MDD and combination
therapy 57–72% MDD. Compliance was consistent. The
combination therapy cohorts tended to have significantly
higher (p  .05) pharmacy costs than the monotherapy
cohorts. The study did not conclusively support differ-
ences in medical costs between the cohorts. CONCLU-
SION: Therapy in all cohorts changed before MDD of
the original agent was attempted. Patients in each cohort
progressed to insulin monotherapy without a recom-
mended trial of combination agents. Although pharmacy
and medical costs influence the total cost of diabetic care,
there was no significant difference in medical costs identi-
fied. Cost differences were driven by pharmacy costs.
PDB2
USING RETROSPECTIVE CLAIMS DATA TO 
DESIGN CLINICAL SAFETY SURVEILLANCE OF 
THIAZOLIDINEDIONE DRUGS
Henriques C1, Schultz D2, Milanette T1, Todoroff K1, Kim M1
1Solucient, Waltham, MA, USA; 2Solucient, Ann Arbor, MI, USA
HYPOTHESIS: Prescription patterns for the newer thia-
zolidinedione (TZD) drugs, pioglitazone and rosiglita-
zone, will reflect historic prescription patterns for trogli-
tazone. Predicting what drugs are commonly prescribed
in combination with pioglitazone and rosiglitazone might
help anticipate the most common drug interactions for
these drugs, and possible adverse effects due to additive
drug toxicity. This information can be used to design sur-
veillance monitoring to detect toxicity due to additive
effects early. If this type of toxicity is detected, recom-
mendations for multidrug regimens can be revised appro-
priately. METHODS: This retrospective data analysis
used data from Solucient’s proprietary Medical Claims
Data Warehouse of over 6 million lives. Patients in the
troglitazone cohort took troglitazone for at least 4 con-
secutive months between 9/1/1998 and 6/30/2000, and
had at least one other prescription for a diabetic drug
written after the last troglitazone prescription. Patients in
the pioglitazone and rosiglitazone cohorts took pioglita-
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